Haematological Cancers

  • T. J. Priestman

Abstract

The haematological cancers account for only about 5 per cent of malignancies but cytotoxic therapy plays a major part in their management and has brought about a dramatic improvement in the prognosis for many of these tumours, offering the possibility of cure in a significant number of patients. The haematological cancers are a very diverse group of diseases, the principal members of which are the leukaemias and lymphomas. The leukaemias are characterised by the production of excessive numbers of white blood cells and many different forms of the disease exist. These are classified into four major groups: acute lymphoblastic leukaemia, acute myeloid leukaemia, chronic myeloid leukaemia and chronic lymphoid leukaemia. The lymphomas are primary cancers of the lymphoreticular system: they usually arise in lymph nodes but may originate in any organ containing lymphoid tissue. The disease may remain localised for a variable period of time but, if untreated, all lymphomas will become disseminated and ultimately fatal. The lymphomas are classified under two headings: Hodgkin’s disease and the non-Hodgkin’s lymphomas. There are a number of other haematological cancers apart from the leukaemias and lymphomas, the two commonest’ of which are multiple myeloma and polycythaemia vera and these will also be considered in this chapter.

Keywords

Interferon Doxorubicin Methotrexate Melphalan Cyclophosphamide 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Leukaemia. Whittaker JA, Delamore IW (editors) Blackwell Scientific Publications, Oxford, 1987Google Scholar
  2. Treatment of childhood acute lymphoblastic leukaemia. Anonymous (1988) Lancet, i: 683–685Google Scholar
  3. Curing children of leukemia. Pinkel D (1987) Cancer, 59: 1683–1691PubMedCrossRefGoogle Scholar
  4. Acute lymphoblastic leukemia. Murphy SB (editor) (1985) Seminars in Oncology, 12: 79–195Google Scholar
  5. Acute myeloid leukemia. Bloomfield CD (editor) (1987) Seminars in Oncology, 14: 357–468Google Scholar
  6. Bone marrow transplantation for patients with chronic myeloid leukaemia. Mackinnon S, Goldman M (1988) British Journal of Hospital Medicine, 22: 226–230Google Scholar
  7. Hodgkin’s and non-Hodgkin’s lymphomas: clinical assessment and treatment. Horwich A in Malignant lymphomas (Eds. Habeshaw JA, Louder I) Churchill Livingstone, Edinburgh, 1988, pp 252–283Google Scholar
  8. Curable cancers: Hodgkin’s and non-Hodgkin’s lymphomas. McElwain TJ (1984) British Journal of Hospital Medicine, 18; 10–19Google Scholar
  9. ABVD versus MOPP: which is better? Rosenberg SA (1987) Journal of Clinical Oncology, 5: 7PubMedGoogle Scholar
  10. MOPP after two decades. Rosenberg SA (1986) Journal of Clinical Oncology, 4; 1289–1290PubMedGoogle Scholar
  11. Polycythaemia vera: an update. Berlin NI (editor) (1986) Seminars in Haematology, 23:131–183Google Scholar
  12. Plasma cell myeloma and the myeloma proteins. Farhangi M (editor) (1986) Seminars in Oncology, 13: 259–380Google Scholar
  13. Management of multiple myeloma. Richards JDM, Singer CRJ, Tobias S (1987) British Journal of Hospital Medicine, 21: 437–442Google Scholar
  14. Management of refractory myeloma: a review. Buzard AC, Dune BGM (1988) Journal of Clinical Oncology, 6: 889–905Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1989

Authors and Affiliations

  • T. J. Priestman
    • 1
  1. 1.Queen Elizabeth HospitalEdgbaston, BirminghamUK

Personalised recommendations